Vigene Biosciences To Be Acquired For Up To $350 Million
May 19, 2021
POTOMAC, MD. — Shulman Rogers’ Mergers and Acquisitions team was pleased to support our client, U.S.-based gene therapy contract development and manufacturing organization, Vigene Biosciences, in their recent agreement to be acquired by Charles River Laboratories for up to $350 million.
Led by Shareholders, Scott Museles and Aaron Ghais and Associates, Keith Marshall and Paul Schwinn, the deal team also included Eric von Vorys, Robert Canter, Meredith “Merry” Campbell, Eric Kurtz, Sara Clasper, Tyler Winters and Hunter Haines. Shulman Rogers and NEXT powered by Shulman Rogers, the Firm’s platform for startup and emerging growth companies, are gratified to support our many clients in the biotech space and especially excited about the involvement of Vigene and Charles River Laboratories in the rapidly expanding gene therapy industry.
Of the transaction, Museles said, “We are proud to have supported Vigene’s significant growth, which will culminate in a sale to Charles River Laboratories, a leading provider of drug discovery and development services.”
With a mission to make gene therapy affordable, Vigene supports scientists at any stage of research from academia, government organizations, research institutes, biotechnology companies and pharmaceutical companies.
Vigene Biosciences ranked 81st , 410th and 638th on the Inc. 5000 list of fastest-growing private companies in America for 2018, 2019 and 2020 respectively, and was also named the 2018 ACG Emerging Company of the Year.
The acquisition will enhance and expand Charles River Laboratories’ existing gene therapy capabilities in the high-growth, value-added cell and gene therapy CDMO sector, and is expected to drive growth and shareholder value.
To read the full press release from Charles River Laboratories, click HERE.